Αρχική World News FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma World News FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma Από Ogkologos - 22 Ιουλίου, 2026 223 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Long-Term Survival in a Significant Proportion of Patients with a 1p/19q... 28 Ιουνίου, 2022 Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors 15 Νοεμβρίου, 2019 Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,... 16 Ιουλίου, 2025 Spotlight On: Pelvic Physical Therapists in Cancer Care 31 Μαρτίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and... Can Topical Drugs Help Prevent Breast Cancer? FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years... What Are Patient-Reported Outcomes and Why Are They Important in Cancer...